MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Sanofi

Fermé

54.58 1.19

Résumé

Variation du prix de l'action

24h

Actuel

Min

53.9

Max

55.68

Chiffres clés

By Trading Economics

Revenu

-2.3B

499M

Ventes

-6.5B

7.6B

P/E

Moyenne du Secteur

23.205

63.778

BPA

0.682

Rendement du dividende

3.67

Marge bénéficiaire

6.539

Employés

82,878

EBITDA

-3.7B

563M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+20.02% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.67%

2.39%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-1.5B

136B

Ouverture précédente

53.39

Clôture précédente

54.58

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Sanofi Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

20 mars 2025, 06:43 UTC

Acquisitions, Fusions, Rachats

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

3 févr. 2025, 13:19 UTC

Acquisitions, Fusions, Rachats

L'Oreal to Sell $3.1 Billion Stake in Sanofi Back to Pharma Group -- Update

3 févr. 2025, 09:31 UTC

Acquisitions, Fusions, Rachats

Correction to L'Oreal article

3 févr. 2025, 07:09 UTC

Acquisitions, Fusions, Rachats

L'Oreal Agrees to Sell Back 2.3% Stake in Sanofi for $3.1 Billion

30 janv. 2025, 11:09 UTC

Résultats

Correction to Sanofi Article

30 janv. 2025, 06:47 UTC

Résultats

Sanofi Issues $5.2 Billion Share Buyback; Expects Sales, Core Earnings Growth

2 avr. 2025, 09:27 UTC

Actions en Tendance

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

20 mars 2025, 06:05 UTC

Acquisitions, Fusions, Rachats

Sanofi: Deal Seeks to Broaden Immunology Pipeline

20 mars 2025, 06:05 UTC

Acquisitions, Fusions, Rachats

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

20 mars 2025, 06:04 UTC

Acquisitions, Fusions, Rachats

Sanofi to Pay $600M Upfront

20 mars 2025, 06:02 UTC

Acquisitions, Fusions, Rachats

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

20 mars 2025, 06:00 UTC

Acquisitions, Fusions, Rachats

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

19 févr. 2025, 06:35 UTC

Acquisitions, Fusions, Rachats

Sanofi: Transaction Remains Subject to Obtaining Customary Regulatory Approvals

19 févr. 2025, 06:34 UTC

Acquisitions, Fusions, Rachats

Sanofi: Closing Is Expected to Take Place in 2Q at the Earliest

19 févr. 2025, 06:34 UTC

Acquisitions, Fusions, Rachats

Sanofi: Terms of Transaction Remain Unchanged From Those Previously Disclosed

19 févr. 2025, 06:33 UTC

Acquisitions, Fusions, Rachats

Sanofi to Remain Significant Shareholder in Opella Consumer Business

19 févr. 2025, 06:33 UTC

Acquisitions, Fusions, Rachats

Sanofi: Bpifrance to Participate as Minority Shareholder With 2% Stake in Opella

19 févr. 2025, 06:33 UTC

Acquisitions, Fusions, Rachats

Sanofi: This Follows Completion of Required Social and Corporate Procedures

19 févr. 2025, 06:32 UTC

Acquisitions, Fusions, Rachats

Sanofi Signs Deal for Sale of 50% Controlling Stake in Opella to CD&R

19 févr. 2025, 06:31 UTC

Acquisitions, Fusions, Rachats

Sanofi, CD&R Sign Opella Share Purchase Agreement

3 févr. 2025, 06:37 UTC

Acquisitions, Fusions, Rachats

Sanofi Says Transaction Is Part of Its Share Buyback Program

3 févr. 2025, 06:35 UTC

Acquisitions, Fusions, Rachats

L'Oreal: Sale Should Be Finalized in Coming Days

3 févr. 2025, 06:35 UTC

Acquisitions, Fusions, Rachats

L'Oreal: Transaction Will Optimize Balance Sheet, Diversify Financing Sources

3 févr. 2025, 06:34 UTC

Acquisitions, Fusions, Rachats

L'Oreal Says It Remains Important Sanofi Shareholder, Fully Supports Strategy

3 févr. 2025, 06:33 UTC

Acquisitions, Fusions, Rachats

L'Oreal Will Own 7.2% of Sanofi's Capital, 13.1% of Voting Rights After Transaction

3 févr. 2025, 06:32 UTC

Acquisitions, Fusions, Rachats

L'Oreal Selling 2.3% Stake in Sanofi for EUR101.50 a Share

3 févr. 2025, 06:31 UTC

Acquisitions, Fusions, Rachats

L'Oreal to Sell Sanofi Stake for EUR3B

3 févr. 2025, 06:31 UTC

Acquisitions, Fusions, Rachats

L'Oreal to Sell Sanofi Stake Back to Sanofi

30 janv. 2025, 10:47 UTC

Market Talk
Résultats

Sanofi's Buyback and Increased R&D Spending Are Positive -- Market Talk

30 janv. 2025, 10:31 UTC

Market Talk
Résultats

Sanofi's Lung Drug Beyfortus Sales Beat Stands Out Among 4Q Results -- Market Talk

Comparaison

Variation de prix

Sanofi prévision

Objectif de Prix

By TipRanks

20.02% hausse

Prévisions sur 12 Mois

Moyen 64.75 USD  20.02%

Haut 67 USD

Bas 63 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

6 ratings

3

Achat

3

Maintien

0

Vente

Score Technique

By Trading Central

N/A / 55.4Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Strong Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.